시간 외 거래: 1.37

Tempest Therapeutics Inc (TPST)

Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스

Tempest Therapeutics Inc (TPST)

Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스

Scotiabank initates Tempest Therapeutics Inc (TPST) rating to a Sector outperform - Knox Daily

Quarterly Metrics: Quick and Current Ratios for Tempest Therapeutics Inc (TPST) - The Dwinnex

Sigourney Weaver to star in Jamie Lloyd's 'The Tempest' this fall - LondonTheatre.co.uk

A Closer Look at Tempus AI Inc. (TEM) Stock Gains - The InvestChronicle

The Tempest cast announced to join Sigourney Weaver at the Theatre Royal Drury Lane in London - WestEndTheatre.com

See Who's Joining Sigourney Weaver in West End The Tempest - Playbill

Davidson Kempner Capital Management LP Acquires New Shares in Tempus AI, Inc. (NASDAQ:TEM) - MarketBeat

Full Cast Announced for The Tempest at Theatre Royal Drury Lane - London Theatre 1

Gavin & Stacey star joins Sigourney Weaver in The Tempest - RadioTimes

The Tempest with Sigourney Weaver at Theatre Royal Drury Lane announces complete casting - WhatsOnStage.com

Full cast announced for Jamie Lloyd Company’s THE TEMPEST at Theatre Royal Drury Lane - West End Best Friend

Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $45.56 - MarketBeat

Tempus AI (NASDAQ:TEM) Shares Gap Up to $50.09 - Defense World

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Tempus AI (NASDAQ:TEM) Shares Down 5.3% - Defense World

Deeper Dive: Understanding Tempus AI Inc. (TEM) Through its Various Ratios - The Dwinnex

Just the Facts: Tempest Minerals begins fieldwork at Five Wheel Project - Proactive Investors UK

Tempus AI Inc. [TEM] Investment Guide: What You Need to Know - Knox Daily

Keeping an Eye on Tempest Therapeutics Inc (TPST) After Insider Trading Activity - Knox Daily

An analyst sees good growth prospects for Tempus AI Inc. (TEM) - SETE News

Tempest Further Strengthens Leadership Team with - GlobeNewswire

Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs - StockTitan

Tempest Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle

An Analysis of Tempest Therapeutics Inc (TPST)’s Potential Price Growth - Knox Daily

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Tempest Therapeutics Inc [TPST] Records 200-Day SMA of $3.1810 - Knox Daily

Is Tempest Therapeutics Inc (TPST) worth investing in despite its undervalued state? - US Post News

Scotiabank initates Tempest Therapeutics Inc (TPST) stock to a Sector outperform - Knox Daily

Anchoring Your Portfolio: Is TPST Stock a Safe Harbor? - The InvestChronicle

Ratios Uncovered: Breaking Down Tempest Therapeutics Inc (TPST)’s Trailing Twelve Months Metrics - The Dwinnex

You might want to take a look at Tempest Therapeutics Inc (TPST) now - SETE News

The Attractiveness of Investing In Tempest Therapeutics Inc (TPST) is Growing - Knox Daily

Investor’s Toolkit: Key Ratios for Assessing Tempest Therapeutics Inc (TPST)’s Performance - The Dwinnex

How To Buy Tempest Therapeutics Inc. Stock Online in August 2024 - Traders Union

Should investors be concerned about Tempest Therapeutics Inc (TPST)? - US Post News

TPST’s 2023 Market Dance: Down -67.73% – Time to Invest? - The InvestChronicle

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Tempest Therapeutics Inc [TPST] Owner makes an insider purchase of 387,999 shares worth 0.43 million. - Knox Daily

Tempest Therapeutics appoints new VP of Quality Assurance - Investing.com

Check out these key findings about Tempest Therapeutics Inc (TPST) - SETE News

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance - GlobeNewswire

Market Momentum Report: Tempest Therapeutics Inc (TPST)’s Positive Close at 1.46 - The Dwinnex

Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance - StockTitan

Tempest Therapeutics Inc [TPST] Investment Guide: What You Need to Know - Knoxdaily.com

How should investors view Tempest Therapeutics Inc (TPST)? - US Post News

Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? - MSN

Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright - Defense World

Tempest Therapeutics Inc [TPST] Shares Rise 30.25% on Thursday - Knox Daily

TPST’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle

Scotiabank maintains a target on Tempest Therapeutics stock By Investing.com - Investing.com Canada

Tempest Therapeutics aligns with FDA on Phase 3 cancer trial By Investing.com - Investing.com Canada

Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? - Benzinga

Tempest stock jumps on positive FDA feedback (NASDAQ:TPST) - Seeking Alpha

Tempest Therapeutics aligns with FDA on Phase 3 cancer trial - Investing.com

Tempest Therapeutics aligns with FDA on Phase 3 cancer trial By Investing.com - Investing.com Australia

Tempest Therapeutics Inc (TPST) Is Worth Accumulating At Current Levels - Stocks Register

Tempest Therapeutics aligns with FDA on Phase 3 cancer trial By Investing.com - Investing.com India

Tempest Therapeutics aligns with FDA on Phase 3 cancer trial By Investing.com - Investing.com UK

Tempest Announces Successful End-of-Phase 2 Meeting with - GlobeNewswire

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma - StockTitan

Its Stock Has Paid Off Big Time For Tempest Therapeutics Inc - SETE News

Scotiabank slashes price target on Tempest Therapeutics Inc [TPST] – find out why. - The DBT News

Tempest Flounders on News of Test Results - MSN

Tempest Therapeutics, Inc. (NASDAQ:TPST) Major Shareholder Versant Venture Capital Vi, L. Sells 400,000 Shares of Stock - Defense World

Tempest Therapeutics, Inc. (NASDAQ:TPST) Major Shareholder Versant Venture Capital Vi, L. Sells 387,999 Shares - Defense World

Versant entities sell Tempest Therapeutics shares worth over $967k - Investing.com

Tempest Therapeutics Inc Inc. (TPST) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

TPST과 유사한 종목